Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL)

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134875

Published: 2020

Journal Articles

Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation

Paola Minetto, MD PhD, Anna Candoni, Fabio Guolo, MD, Marino Clavio, MD, Maria Elena Zannier, MD, Maurizio Miglino, PhD, Maria Vittoria Dubbini, MD, Anna Sicuranza, PhD, Sara Ciofini, Elisabetta Tedone, Nicoletta Colombo, PhD, Girolamo Pugliese, Filippo Ballerini, MD, Michele Cea, Monica Bocchia, Renato Fanin, MD, Roberto Massimo Lemoli, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-142887

Published: 2020

Journal Articles

Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Guido Gini, MD, Monica Tani, Alessandra Tucci, MD, Renato Bassan, MD, Filippo Ballerini, MD, Michela Sampaolo, Francesco Merli, MD, Francesca Re, Attilio Olivieri, Ombretta Annibali, Anna Marina Liberati, Carlo Visco, Annalisa Arcari, MD, Sergio Storti, MD, Alberto Fabbri, MD, Gerardo Musuraca, MD, Vittorio Ruggero Zilioli, MD, M. Christina Cox, MD PhD, Stefano Luminari, MD

Blood (2019) 134 (Supplement_1): 2880.

https://doi.org/10.1182/blood-2019-126568

Published: 2019

Journal Articles

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Blood (2019) 134 (Supplement_1): 3828.

https://doi.org/10.1182/blood-2019-131303

Published: 2019

Journal Articles

Addition of the Anti-CD33 Monoclonal Antibody Mylotarg to Fludarabine/High Dose Cytarabine - Based Induction Significantly Improves Outcome in Patient Affected By FLT3-ITD Positive Cytogenetically Normal Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1365.

https://doi.org/10.1182/blood-2019-131420

Published: 2019

Journal Articles

Adoptive Cell Therapy and Immune Check Points Inhibitors As a Salvage Treatment for Patient Affected By Relapsed/Refractory Hodgkin's Lymphoma

Fabio Guolo, MD, Paola Minetto, MD, Filippo Ballerini, MD, Elisabetta Tedone, Paola Contini, Rosa Mangerini, Alessandra Bo, MD, Maria Carla De Luigi, MD, Paolo Carlier, MD, Alberto Serio, Paolo Strada, MD, Silvia Luchetti, Marco Gobbi, MD, Emanuela Marcenaro, PhD, Roberto Massimo Lemoli, MD

Blood (2019) 134 (Supplement_1): 3231.

https://doi.org/10.1182/blood-2019-130740

Published: 2019

Journal Articles

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

Blood (2018) 132 (Supplement 1): 401.

https://doi.org/10.1182/blood-2018-99-110289

Published: 2018

Journal Articles

A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML

Fabio Guolo, MD, Paola Minetto, MD, Annalisa Kunkl, MD, Elisabetta Tedone, Marino Clavio, MD, Maurizio Miglino, PhD, Fabrizio Caviglia, Nicoletta Colombo, PhD, Antonia Cagnetta, MD, Michele Cea, MD, Filippo Ballerini, MD, Jean Louis Ravetti, MD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD

Blood (2018) 132 (Supplement 1): 5243.

https://doi.org/10.1182/blood-2018-99-118984

Published: 2018

Journal Articles

Feasibility of High Doses Peg-Asparaginase Administration in a Cohort of Adult Acute Lymphoblastic Leukemia Patients

Paola Minetto, MD, Nadia Bisso, MD, Fabio Guolo, MD, Marino Clavio, MD, Riccardo Marcolin, MD, Filippo Ballerini, MD, Maurizio Miglino, PhD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD

Blood (2018) 132 (Supplement 1): 5164.

https://doi.org/10.1182/blood-2018-99-119787

Published: 2018

Journal Articles

Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2018-99-118901

Published: 2018

Journal Articles

Patient and Therapy-Related Factors Affecting the Toxicity of Pegylated-Asparaginase for the Treatment of Adult Acute Lymphoblastic Leukemia

Paola Minetto, MD, Nadia Bisso, MD, Fabio Guolo, MD, Marino Clavio, MD, Elisa Coviello, MD, Daniela Guardo, MD, Filippo Ballerini, MD, Maurizio Miglino, PhD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD

Blood (2017) 130 (Supplement 1): 1297.

https://doi.org/10.1182/blood.V130.Suppl_1.1297.1297

Published: 2017

Journal Articles

Pre-Transplant Minimal Residual Disease Evaluation Performed By Molecular WT1-Based or Multicolor Flow Cytometry Assessment Overcomes the Prognostic Value of Cytogenetic and Molecular Risk Factors at Diagnosis in Advanced Acute Myeloid Leukemia Patients

Fabio Guolo, MD, Paola Minetto, MD, Marino Clavio, MD, Nicoletta Colombo, PhD, Annalisa Kunkl, MD, Enrico Carminati, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Filippo Ballerini, MD, Maurizio Miglino, PhD, Emanuele Angelucci, Roberto M Lemoli, MD, Marco Gobbi, MD

Blood (2017) 130 (Supplement 1): 3316.

https://doi.org/10.1182/blood.V130.Suppl_1.3316.3316

Published: 2017

Journal Articles

Early Minimal Residual Disease Assessment after Acute Myeloid Leukemia Induction with Fludarabine Cytarabine and Idarubicin (FLAI) Provides the Most Useful Prognostic Information

Paola Minetto, MD, Fabio Guolo, MD, Marino Clavio, MD, Annalisa Kunkl, MD, Nicoletta Colombo, PhD, Enrico Carminati, Giuseppina Fugazza, Simona Matarese, MD, Daniela Guardo, MD, Filippo Ballerini, MD, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Antonia Cagnetta, MD, Michele Cea, Maurizio Miglino, PhD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD

Blood (2017) 130 (Supplement 1): 5047.

https://doi.org/10.1182/blood.V130.Suppl_1.5047.5047

Published: 2017

Journal Articles

Comparison of the Efficacy and Feasibility of R-CODOX-M/IVAC-R Versus Conventional R-CHOP As First Line Regimen for High Risk Diffuse Large B-Cell Lymphoma

Giulia Bartalucci, MD, Elisa Coviello, MD, Fabio Guolo, MD, Paola Minetto, MD, Massimiliano Gambella, Giulia Rivoli, MD, Daniela Guardo, MD, Filippo Ballerini, MD, Maurizio Miglino, PhD, Alberto Fabbri, MD, Roberto M Lemoli, MD, Monica Bocchia, Marco Gobbi, MD

Blood (2017) 130 (Supplement 1): 2851.

https://doi.org/10.1182/blood.V130.Suppl_1.2851.2851

Published: 2017

Journal Articles

Minimal Residual Disease Assessment May Drive Post Remission Therapy in Acute Myeloid Leukemia. It's Time for MRD-Driven Therapy

Paola Minetto, MD, Fabio Guolo, MD, Marino Clavio, MD, Annalisa Kunkl, MD, Filippo Ballerini, MD, Nicoletta Colombo, PhD, Enrico Carminati, Giuseppina Fugazza, Giordana Pastori, MD, Simona Matarrese, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Andrea Bacigalupo, MD, Roberto Massimo Lemoli, MD, Maurizio Miglino, PhD, Marco Gobbi, MD

Blood (2016) 128 (22): 2895.

https://doi.org/10.1182/blood.V128.22.2895.2895

Published: 2016

Journal Articles

Identification of DNA Copy Number Variations Associated with the Clinical Outcome in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation in the Prospective from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL)

Andrea Rinaldi, PhD, Simone Ferrero, Ivo Kwee, PhD, Davide Rossi, MD PhD, Alessio Bruscaggin, Valeria Spina, Fary Diop, Filippo Ballerini, MD, Filippo Gherlinzoni, MD, Fabio Benedetti, Michael Mian, MD, Caterina Stelitano, MD, Elisa Doni, MD, Alessandra Flavia Salvi, Sergio Cortelazzo, Marco Ladetto, MD, Gianluca Gaidano, MD PhD, Francesco Bertoni, MD

Blood (2016) 128 (22): 4099.

https://doi.org/10.1182/blood.V128.22.4099.4099

Published: 2016

Journal Articles

Finding the Best Therapy for Elderly Frail AML Patients: A Retrospective Comparison of 5-Azacytidine and Intensive Approach

Giordana Pastori, MD, Fabio Guolo, MD, Paola Minetto, MD, Marino Clavio, MD, Enrico Balleari, MD, Nicoletta Colombo, Biologist, Giulia Rivoli, MD, Lisette Del Corso, MD, Filippo Ballerini, MD, Livia Giannoni, MD, Laura Mitscheunig, MD, Clara Dellepiane, Daniela Guardo, MD, Maurizio Miglino, PhD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD

Blood (2016) 128 (22): 5202.

https://doi.org/10.1182/blood.V128.22.5202.5202

Published: 2016

Journal Articles

Combining Flow Cytometry and Molecular Assessment Improves the Prognostic Value of Pre-Transplant Minimal Residual Disease in Acute Myeloid Leukemia

Fabio Guolo, MD, Paola Minetto, MD, Federica Galaverna, MD, Daniela Guardo, MD, Nicoletta Colombo, PhD, Annalisa Kunkl, MD, Marino Clavio, MD, Carmen Di Grazia, MD, Anna Maria Raiola, MD, Filippo Ballerini, MD, Maurizio Miglino, PhD, Roberto Massimo Lemoli, MD, Marco Gobbi, MD, Andrea Bacigalupo, MD

Blood (2016) 128 (22): 521.

https://doi.org/10.1182/blood.V128.22.521.521

Published: 2016

Journal Articles

SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia

Michele Cea, MD, Antonia Cagnetta, MD, Debora Soncini, PhD, Paola Minetto, MD, Davide Lovera, MD, Fabio Guolo, MD, Nicoletta Colombo, PhD, Filippo Ballerini, MD, Marino Clavio, MD, Maurizio Miglino, PhD, Marco Gobbi, MD, Roberto M Lemoli, MD

Blood (2016) 128 (22): 5222.

https://doi.org/10.1182/blood.V128.22.5222.5222

Published: 2016

Journal Articles

A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia

Michele Cea, MD, Antonia Cagnetta, MD, Davide Lovera, MD, Raffaella Grasso, PhD, Nicoletta Colombo, PhD, Micaela Bergamaschi, MD, Sara Aquino, MD, Fabio Guolo, MD, Paola Minetto, MD, Filippo Ballerini, MD, Letizia Canepa, MD, Sophia Adamia, PhD, Alessio Nencioni, Ivana Pierri, MD, Marino Clavio, Maurizio Miglino, PhD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD

Blood (2015) 126 (23): 1375.

https://doi.org/10.1182/blood.V126.23.1375.1375

Published: 2015

NARROW

Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL)

Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation

Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Addition of the Anti-CD33 Monoclonal Antibody Mylotarg to Fludarabine/High Dose Cytarabine - Based Induction Significantly Improves Outcome in Patient Affected By FLT3-ITD Positive Cytogenetically Normal Acute Myeloid Leukemia

Adoptive Cell Therapy and Immune Check Points Inhibitors As a Salvage Treatment for Patient Affected By Relapsed/Refractory Hodgkin's Lymphoma

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML

Feasibility of High Doses Peg-Asparaginase Administration in a Cohort of Adult Acute Lymphoblastic Leukemia Patients

Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma

Patient and Therapy-Related Factors Affecting the Toxicity of Pegylated-Asparaginase for the Treatment of Adult Acute Lymphoblastic Leukemia

Pre-Transplant Minimal Residual Disease Evaluation Performed By Molecular WT1-Based or Multicolor Flow Cytometry Assessment Overcomes the Prognostic Value of Cytogenetic and Molecular Risk Factors at Diagnosis in Advanced Acute Myeloid Leukemia Patients

Early Minimal Residual Disease Assessment after Acute Myeloid Leukemia Induction with Fludarabine Cytarabine and Idarubicin (FLAI) Provides the Most Useful Prognostic Information

Comparison of the Efficacy and Feasibility of R-CODOX-M/IVAC-R Versus Conventional R-CHOP As First Line Regimen for High Risk Diffuse Large B-Cell Lymphoma

Minimal Residual Disease Assessment May Drive Post Remission Therapy in Acute Myeloid Leukemia. It's Time for MRD-Driven Therapy

Finding the Best Therapy for Elderly Frail AML Patients: A Retrospective Comparison of 5-Azacytidine and Intensive Approach

Combining Flow Cytometry and Molecular Assessment Improves the Prognostic Value of Pre-Transplant Minimal Residual Disease in Acute Myeloid Leukemia

SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia

A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only